Abdera Therapeutics
Philippe Bishop MD is a seasoned medical professional with extensive experience in oncology and drug development. Currently serving as the Chief Medical Officer at Abdera Therapeutics since January 2024, Philippe Bishop previously held similar roles at Atreca, Inc. and Clover Biopharmaceuticals, where involvement included the development of novel vaccines and therapeutic candidates. Philippe Bishop co-founded aratinga.bio, focusing on innovative cancer immunotherapies. Additionally, Philippe Bishop has held leadership positions at Gilead Sciences, Genentech, Johnson & Johnson, sanofi-aventis, and the FDA, contributing to significant advancements in drug registration and clinical development throughout a distinguished career that began with an oncology fellowship at the National Cancer Institute.
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.